Psychotropic drug use during pregnancy: Weighing the risks

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 2, 1998, Pages 18-28

  Cohen, Lee S ^a   Rosenbaum, Jerrold F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; DRUG SAFETY; DRUG USE; FEMALE; FETUS DEATH; FOOD AND DRUG ADMINISTRATION; HUMAN; MENTAL DISEASE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; TERATOGENESIS;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; DEPRESSIVE DISORDER; FEMALE; HUMANS; LITHIUM; MENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOTROPIC DRUGS; RISK ASSESSMENT;

EID: 0031980759     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (190)

1. Cohen LS, Rosenbaum JF, Heller VH. Psychotropic drug use in pregnancy. In: Gelenberg AJ, Bassuk EL, Schoonover SC, eds. The Practitioner's Guide to Psychoactive Drugs. New York, NY: Plenum Medical Book Company; 1991:389-405
2. Doering JC, Stewart RB. The extent and character of drug consumption during pregnancy. JAMA 1978;239:843-846
3. Kasilo O, Romero M, Bonati M, et al. Information on drug use in pregnancy from the Viewpoint Regional Drug Information Center. Eur J Clin Pharmacol 1988;35:447-453
4. Kupfer D, Frank E, Perel J, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992;49:769-773
5. Suppes T, Baldessarini RJ, Faedda GL, et al. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991;48:1082-1088
6. Roy-Byrne PP, Dager SR, Cowley DS, et al. Relapse and rebound following discontinuation of benzodiazepine treatment of panic attacks: alprazolam versus diazepam. Am J Psychiatry 1989;146:860-865
7. Dencker SJ, Malm U, Lepp M. Schizophrenic relapse after drug withdrawal is predictable. Acta Psychiatr Scand 1986;73:181-185
8. Cohen LS, Heller VL, Rosenbaum JF. Treatment guidelines for psychotropic drug use in pregnancy. Psychosomatics 1989;30:25-33
9. Altshuler LL, Cohen LS, Szuba MP, et al. Pharmacologic management of psychiatric illness in pregnancy: dilemmas and guidelines. Am J Psychiatry 1996;153:592-606
10. Calabrese JR, Gulledge AD. Psychotropics during pregnancy and lactation: a review. Psychosomatics 1985;26:413-426
11. Miller L. Clinical strategies for the use of psychotropic drugs during pregnancy. Psychiatr Med 1991;9(2):275-298
12. Mortola J. The use of psychotropic agents in pregnancy and lactation. Psychiatr Clin North Am 1989;12(1):69-87
13. Robinson GE, Stewart DE, Flak E. The rational use of psychotropic drugs in pregnancy and postpartum. Can J Psychiatry 1986;31:183-190
14. Slone D, Siskind V, Heinonen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977;128:486-488
15. Rumeau-Rouguette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1977;15:57-64
16. Milkovich L, Van den Berg BJ. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol 1976;125:244-248
17. Edlund MJ, Craig TJ. Antipsychotic drug use and birth defects: an epidemiologic reassessment. Compr Psychiatry 1984;25:32-37
18. Kuenssberg EV, Knox JD. Imipramine in pregnancy. BMJ 1972;2:292
19. Idanpaan-Heikkila J, Saxen L. Possible teratogenicity of imipramine-chloropyramine. Lancet 1973;2:282-284
20. Czeizel A, Lendvay A. In-utero exposure to benzodiazepines [letter]. Lancet 1987;1:628
21. Shiono PH, Mills IL. Oral clefts and diazepam use during pregnancy [letter]. N Engl J Med 1984;311:919-920
22. Rosenberg L, Mitchell AA, Parsells JL, et al. Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 1983;309:1282-1285
23. Markovitz PJ, Calabrese JR. Use of anticonvulsants for manic depression in pregnancy [letter]. Psychosomatics 1990;31:118
24. Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:1661-1666
25. Lindhout D, Schmidt D. In utero exposure to valproate and neural defects. Lancet 1986;1:329-393
26. Jacobson SJ, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992;339:530-533
27. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994;271:146-150
28. Istvan J. Stress, anxiety, and birth outcome: a critical review of the evidence. Psychol Bull 1986;100(3):331-348
29. Steer RA, Scholl TO, Hediger ML, et al. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992;45:1093-1099
30. Orr S, Miller C. Maternal depressive symptoms and the risk of poor pregnancy outcome: review of the literature and preliminary findings. Epidemiol Rev 1995;17(1):165-171
31. Perkin MR, Bland JM, Peacock JL, et al. The effect of anxiety and depression during pregnancy on obstetric complications. Br J Obstet Gynaecol 1993;100:629-634
32. Zuckerman B, Bauchner H, Parker S, et al. Maternal depressive symptoms during pregnancy, and newborn irritability. J Dev Behav Pediatr 1990;11 (4):190-194
33. Cutrona CE. Causal attributions and perinatal distress. J Abnorm Psychol 1983;92:161-172
34. Sapolski R, Meaney M. Maturation of the adrenotcortical stress response: neuroendocrine control mechanisms and the stress hyporesponsive period. Brain Res Rev 1986;11:65-76
35. Dicke JM. Teratology: principles and practice. Med Clin North Am 1989; 73:567-581
36. American Medical Association. Drug interactions and adverse drug reactions. In: American Medical Association Drug Evaluation. Chicago, Ill: American Medical Association; 1983:31-44
37. Fabro SE. Clinical Obstetrics. New York, NY: John Wiley & Sons; 1987
38. Langman J. Human development: normal and abnormals. In: Langman J, ed. Medical Embryology. Baltimore, Md: Williams & Wilkins; 1985:123
39. Coyle I, Wayner M, Singer G. Behavioral teratogenesis: a critical evaluation. Pharmacol Biochem Behav 1976;4:191-200
40. Vorhees C, Brunner R, Butcher R. Psychotropic drugs as behavioral teratogens. Science 1979;205:1220-1225
41. Vernadakis A, Parker K. Drugs and the developing central nervous system. Pharmacol Ther 1980;11:593-647
42. Robertson RT, Majka JA, Peter CP, et al. Effects of prenatal exposure to chlorpromazine on postnatal development and behavior of rats. Toxicol Appl Pharmacol 1980;53:541-549
43. Kellogg CK. Benzodiazepines: influence on the developing brain. Prog Brain Res 1988;73:207-228
44. Kellogg C, Ison J, Miller J. Prenatal diazepam exposure: effects on auditory temporal resolution in rats. Psychopharmacology (Berl) 1983;79:332-337
45. Montero D, DeCeballos M, DelRio J. Down-regulation of 3H-imipramine binding sites in rat cerebral cortex after prenatal exposure to antidepressants. Life Sci 1990;46:1619-1626
46. Miller GC, Friedhoff AG. Prenatal neurotransmitter programming of postnatal receptor function. Prog Brain Res 1987;2:509-522
47. Lauer JA, Adams PM, Johnson KM. Perinatal diazepam exposure: behavioral and neurochemical consequences. Neurotoxicol Teratol 1989;9: 213-219
48. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991;21(2):157-171
49. Laegreid L, Hagberg G, Lundberg A. The effect of benzodiazepines on the fetus and the newborn. Neuropediatrics 1992;23:18-23
50. Schou M. What happened later to the lithium babies: a follow-up study of children born without malformations. Acta Psychiatr Scand 1976;54: 193-197
51. Nulman I, Rovet J, Stewart D, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-262
52. Eggermont E. Withdrawal symptoms in neonates associated with maternal imipramine therapy. Lancet 1973;2:680
53. Schimmel M, Katz E, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. Clinical Toxicology 1991;29:479-484
54. Webster PAC. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973;2:318-319
55. Shearer WT, Schreiner RL, Marshall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 1972;81: 570-572
56. Tamer A, McKey R, Arias D, et al. Phenothiazine-induced extrapyramidal dysfunction in the neonate. J Pediatr 1969;75:479-480
57. Falterman LG, Richardson DJ. Small left colon syndrome associated with maternal ingestion of psychotropics. J Pediatr 1980;97:300-310
58. Scokel PW, Jones WD. Infant jaundice after phenothiazine drugs for labour: an enigma. Obstet Gynecol 1962;20:124-127
59. Hill RM, Desmond MM, Kay JL. Extrapyramidal dysfunction in an infant of a schizophrenic mother. J Pediatr 1966;69:589-595
60. Fisher J, Edgren B, Mammel M. Neonatal apnea associated with maternal clonazepam therapy. Obstet Gynecol 1985;66(3, suppl)34S-35S
61. Athinarayanan P, Peirog S, Nigam S. Chlordiazepoxide withdrawal in the neonate. Am J Obstet Gynecol 1976;124:212-213
62. Gillberg C. "Floppy infant death syndrome" and maternal diazepam [letter]. Lancet 1977;2:244
63. Mazzi E. Possible neonatal diazepam withdrawal: a case report. Am J Obstet Gynecol 1977;129:586-587
64. Whitelaw A, Cummings A, McFadyen I. Effect of maternal lorazepam on the neonate. BMJ 1981;282:1106-1108
65. Pollack MH, Otto MW, Rosenbaum JF, et al. Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry 1990;51(12, suppl A):12-16
66. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990;47:1106-1111
67. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999-1010
68. Cohen LS, Rosenbaum JF, Heller VL. Panic attack-associated placental abruption: a case report. J Clin Psychiatry 1989;50:266-267
69. Kopelman AE, McCullar FW, Heggeness L. Limb malformations following maternal use of haloperidol. JAMA 1975;231:62-64
70. Hanson G, Oakley G. Haloperidol and limb deformity [letter]. JAMA 1975;231:26
71. van Waes A, van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidum. J Clin Psychopharmacol 1969;224-237
72. Waldman M, Safferman A. Pregnancy and clozapine. Am J Psychiatry 1993;150:168-169
73. Levy W, Wisniewski K. Chlorpromazine causing extrapyramidal dysfunction in newborn infants of psychotic mothers. New York State Journal of Medicine 1974;74:684-685
74. Auerbach JG, Hans SL, Marcus J, et al. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol 1992;14:399-406
75. Desmond MM, Rudolph AJ, Hill RM. Behavioral alterations in infants born to mothers on psychoactive medication during pregnancy. In: Farrell G, ed. Congenital Mental Retardation. Austin, Tex: University of Texas; 1967
76. Clarke C, Gorman D, Vernadakis A. Effects of prenatal administration of psychotropic drugs on behavior of developing rats. Dev Psychol 1970;3: 225-235
77. Golub M, Kornetsky C. Seizure susceptibility and avoidance conditioning in adult rats treated prenatally with chlorpromazine. Dev Psychobiol 1974; 7:79-88
78. Spear LP, Shalaby IA, Brick J. Chronic administration of haloperidol during development: behavioral and psychopharmacological effects. Psychopharmacology 1980;70:47-58
79. Cagiano R, Barfield R, White N. Subtle behavioral changes produced in rat pups exposed in utero to haloperidol. Eur J Pharmacol 1988;157:45-50
80. Zajicek E. Psychiatric problems during pregnancy. In: Wolkind S, Zajicek E, eds. Pregnancy: a Psychological and Social Study. London, England: Academic Press; 1981:57-73
81. O'Hara MW, Schlechte JA, Lewis DA, et al. Controlled prospective study of postpartum mood disorders: psychological, environmental, and hormonal factors. J Abnorm Psychol 1991;100:63-73
82. Cohen LS, Grush L, Goldstein J, et al. Relapse of recurrent major depression during pregnancy. Presented at the Paper Session of the annual meeting of the American Psychiatric Association; May 17-22, 1997; San Diego, Calif
83. Kessler RC, McGonagle KA, Swartz M, et al. Sex and depression in the National Comorbidity Survey, I: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29:85-96
84. McBride WG. Limb deformities associated with ininodibenzyl hydrochloride [letter]. Med J Aust 1972;1:492
85. Heinonen O, Sloan D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, Mass: Publishing Services Group; 1977
86. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269: 2246-2248
87. Crombie D, Pinsent RJ, Felming D. Imipramine and pregnancy [letter]. BMJ 1972;1:745
88. Rachelefsky G, Flynt J, Ebbin A. Possible teratogenicity of tricyclic antidepressants. Lancet 1972;1:838
89. Sim M. Imipramine and pregnancy. BMJ 1972;2:45
90. Scanlon F. Use of antidepressant drugs first trimester [letter]. Med J Aust 1969;2(21):1077
91. Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation. Baltimore, Md: William & Wilkins; 1994
92. Banister P, Dafoe C, Smith ESO, et al. Possible teratogenicity of tricyclic antidepressants [letter]. Lancet 1972;1:838-839
93. Morrow AW. Imipramine and congenital abnormalities. N Z Med J 1972; 75:228-229
94. Jacobs D. Imipramine (Tofranil) [letter]. S Afr Med J 1972;46:1023
95. Cowe L, Lloyd D, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. BMJ 1982;284:1837-1838
96. Ali S, Buelkesam J, Newport L. Early neurobehavioral and neurochemical alterations in rats prenatally exposed to imipramine. Neurotoxicology 1986;7:365-380
97. DelRio J, Montero D, DeCeballos M. Long lasting changes after perinatal exposure to antidepressants. Prog Brain Res 1988;73:173-187
98. Coyle LR. Changes in developing behavior following prenatal administration. Pharmacol Biochem Behav 1975;3:799-807
99. File SE, Tucker JC. Prenatal treatment with clomipramine: effects on the behavior of male and female adolescent rats. Psychopharmacology (Berl) 1984;82:221-224
100. Jason K, Cooper T, Friedman E. Prenatal exposure to imipramine alters early behavioral development and beta adrenergic receptors in rats. J Pharmacol Exp Ther 1981;217:461-466
101. DeCeballos M, Benedi A, DeFelipe C, et al. Prenatal exposure of rats to antidepressants enhances agonist affinity of brain dopamine receptors and dopamine-mediated behavior. Eur J Pharmacol 1985;116:257-262
102. Pastuszak AL, Milich V, Can S, et al. Prospective assessment of pregnancy outcome following first trimester exposure to benzodiazepines. Presented at the 6th International Conference on Teratogen Information Services; 1993
103. Chambers C, Johnson K, Dick L, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996;335:1010-1015
104. Nulman I, Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology 1996;53:304-308
105. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. Clinical Psychopharmacology 1995;15:417-420
106. McElhatton P, Garbis H, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996;10(4):285-294
107. Cohen LS, Rosenbaum JR. Fluoxetine in pregnancy [letter]. N Engl J Med 1997;336:872
108. Inman W, Kobotu K, Pearce G, et al. Prescription event monitoring of paroxetine. Prescription Events Monitoring Reports 1993;PXL 1206: 1-44
109. Spencer M. Fluoxetine hydrochloride (Prozac) toxicity in the neonate. Pediatrics 1993;92:721-722
110. Cohen LS, Grush LR, Bailey JW, et al. Perinatal outcome following fluoxetine exposure: a preliminary report. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatry Association: May 20, 1997; San Diego, Calif. Abstract NR 212:125
111. Chiarello R, Cole J. The use of psychostimulants in general psychiatry: a reconsideration. Arch Gen Psychiatry 1987;44:286-295
112. Goldstein H, Weinberg J, Sankstone M. Shock therapy in psychosis complicating pregnancy: a case report. Am J Psychiatry 1941;98:201-202
113. Remick RA, Maurice WL. ECT in pregnancy [letter]. Am J Psychiatry 1978;135:761-762
114. Impasato DJ, Gabriel AR, Lardara M. Electric and insulin shock therapy during pregnancy. Dis Nerv Syst 1964;25:542-546
115. Miller LJ. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994;45:444-450
116. Ferrill MJ, Kehoe WA, Jacisin JJ. ECT during pregnancy: physiologic and pharmacologic considerations. Convuls Ther 1992;8(3):186-200
117. Sherer DM, D'Amico LD, Warshal DP, et al. Recurrent mild abruptio placentae occurring immediately after repeated electroconvulsive therapy in pregnancy. Am J Obstet Gynecol 1991;165:652-653
118. Weinstein MR. The International Register of Lithium Babies. Drug Information Journal 1976;10:94-100
119. Schou M, Goldfield MD, Weinstein MR, et al. Lithium and pregnancy, I: report from the register of lithium babies. BMJ 1973;2:135-136
120. Nora JJ, Nora AH, Toews WH. Lithium, Ebstein's anomaly and other congenital heart defects [letter]. Lancet 1974;2:594-595
121. Kallen B, Tandberg A. Lithium and pregnancy: a cohort study on manic-depressive women. Acta Psychiatr Scand 1983;68:134-139
122. Kallen B. Comments on teratogen update: lithium. Teratology 1988;38: 597
123. Edmonds LD, Oakley GP. Ebstein's anomaly and maternal lithium exposure during pregnancy. Teratology 1990;41:551-552
124. Sipek A. Lithium and Ebstein's anomaly. Cor Vasa 1989;31:149-156
125. Zalstein E, Koren G, Einarson T, et al. A case control study on the association between 1st-trimester exposure to lithium and Ebstein's anomaly. Am J Cardiol 1990;65:817-818
126. Schou M, Amdisen A. Lithium and the placenta [letter]. Am J Obstet Gynecol 1975;122:541
127. Woody J, London W, Wilbanks G. Lithium toxicity in a newborn. Pediatrics 1971;47:94-96
128. Ananth J. Side effects of fetus and infant of psychotropic drug use during pregnancy. Pharmacopsychiatry 1976;11:246-260
129. Cohen LS, Sichel DA, Robertson LM, et al. Postpartum prophylaxis for women with bipolar disorder. Am J Psychiatry 1995;152:1641-1645
130. Koch S, Hortman A, Jager-Roman E. Major malformations of children of epileptic parents: due to epilepsy or therapy? In: Janz D, Richens A, eds. Epilepsy, Pregnancy, and the Child. New York, NY: Ram Press; 1982: 313-316
131. Paskind H, Brown M. Constitutional differences between deteriorated and nondeteriorated patient with epilepsy. Archives of Neurology and Psychiatry 1936;36:1037-1044
132. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-677
133. Omtzigt JGC, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl 5):119-125
134. Lammer EJ, Sever LE, Oakley GP. Teratogen update: valproic acid. Teratology 1987;35:465-473
135. Lindhout D, Meinardi H, Meijer J. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern malformations. Neurology 1992;42(suppl 5):94-110
136. Battino D, Binelli S, Caccamo M. Malformation in offspring of 305 epileptic women: a prospective study. Acta Neurol Scand 1992;85:204-207
137. Koch S, Losche G, Jager-Roman E. Major and minor birth malformations and antiepileptic drugs. Neurology 1992;42(suppl 5):83-88
138. Nakane Y, Okuma T, Takahashi R, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980;21:663-680
139. Shaw GM, Wasserman CR, O'Malley CD, et al. Orofacial clefts and maternal anticonvulsant use. Reprod Toxicol 1995;9(1):97-98
140. Aarskog D. Association between maternal intake of diazepam and oral clefts [letter]. Lancet 1975;2:921
141. Safra MJ, Oakley GP. Association between cleft lip with or without cleft palate and prenatal exposure to diazepam. Lancet 1975;2:478-480
142. Saxen I. Association between oral clefts and drugs taken during pregnancy. Int J Epidemiol 1975;4:37-44
143. Milkovich L, van den Berg BJ. Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. N Engl J Med 1974;291:1268-1271
144. Crombie D, Pinsent R, Fleming D. Fetal effects of tranquilizers in pregnancy [letter]. N Engl J Med 1975;293:198-199
145. Hartz S, Heinonen O, Shapiro S. Antenatal exposure to meprobamate and chlordiazepoxide in relation to malformations, mental development, and childhood mortality. N Engl J Med 1975;292:726-728
146. Saxen I, Saxen L. Association between maternal intake of diazepam and oral clefts [letter]. Lancet 1975;2:498
147. Czeizel A. Diazepam, phenytoin and aetiology of cleft lip and/or cleft palate [letter]. Lancet 1976;1:810
148. Czeizel A, Racz J. Evaluation of drug intake during pregnancy in the Hungarian case-control surveillance of congenital anomalies. Teratology 1990;42:505-512
149. Laegreid L, Olegard R, Conradi N, et al. Congenital malformations and maternal consumption of benzodiazepines: a case control study. Dev Med Child Neurol 1990;32:432-441
150. Bergman U, Rosa FW, Baum C, et al. Effects of exposure to benzodiazepine during fetal life. Lancet 1992;340:694-696
151. St. Clair SM, Schirmer RG. First-trimester exposure to alprazolam. Obstet Gynecol 1992;80:843-846
152. Weinstock L, Cohen LS, Sichel DA, et al. Clonazepam use during pregnancy. In: Syllabus & Proceedings Summary of the 1996 Annual Meeting of the American Psychiatric Association; May 4-9, 1996; New York, NY. No 24:11
153. Spielvogel A, Wile J. Treatment and outcomes of psychotic patients during pregnancy and childbirth. Birth 1992;19:131-137
154. Wrede G, Mednick S, Huttenen M. Pregnancy and delivery complications in the births of unselected series of Finnish children with schizophrenic mothers. Acta Psychiatr Scand 1980;62:369-381
155. Miller LJ. Psychotic denial of pregnancy: phenomenology and clinical management. Hosp Community Psychiatry 1990;41:1233-1237
156. Carpenter W, Hanlon T, Heinrichs D, et al. Continuous vs targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138-1141
157. Viguera AC, Baldessarini RC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:189-192
158. Gotlib IH, Whiffen VE, Mount JH, et al. Prevalence rates and demographic characteristics associated with depression in pregnancy and the postpartum period. J Consult Clin Psychol 1989;57:269-274
159. O'Hara MW. Social support, life events, and depression during pregnancy and the pueperium. Arch Gen Psychiatry 1986;43:569-573
160. Cohn JF, Tronick E. Specificity of infants' response to mothers' affective behavior. J Am Acad Child Adolesc Psychiatry 1989;28:242-248
161. Lederman R. Relationship of anxiety, stress, and psychosocial development to reproductive health. Behav Med 1995;21:101-112
162. Beck AT, Rush AJ, Shaw BF, et al. Cognitive therapy of depression. New York, NY: Guilford Press; 1979
163. Klerman GL, Weissman MM, Rounsaville BJ, et al. Interpersonal psychotherapy of depression. New York, NY: Basic Books; 1984
164. Cohen LS, Robertson LM, Goldstein J, et al. Impact of pregnancy on risk for relapse of MDD. In: Syllabus & Proceedings Summary of the 150th Annual Meeting of the American Psychiatric Association; May 17-22, 1997; San Diego, Calif. No. 57:23
165. O'Hara MW, Rehm LP, Campbell SB. Postpartum depression: a role for social network and life stress variables. J Nerv Ment Dis 1983;171: 336-341
166. O'Hara MW, Neunaber DJ, Zekoski EM. A prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol 1984;93:158-171
167. Wisner KL, Wheeler SB. Prevention of recurrent postpartum major depression. Hosp Community Psychiatry 1994;45:1191-1196
168. Brockington IF, Winokur G, Dean C. Puerperal psychosis. In: Brockington IF, Kumar R, eds. Motherhood and Mental Illness. London, England: Academic Press; 1982:37-69
169. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 1987;150:662-673
170. Paffenbarger RA. Epidemiological aspects of mental illness associated with childbearing. In: Brockington IF, Kumar R, eds. Motherhood and Mental Illness. New York, NY: Grune & Stratton; 1982
171. Reich T, Winokur G. Postpartum psychosis in patients with manic depressive disease. J Nerv Ment Dis 1970;151:60-68
172. Kendell RE, Wainwright S, Hailey A, et al. The influence of childbirth on psychiatric morbidity. Psychol Med 1976;6:297-302
173. Viguera AC, Nonacs RM, Cohen LS, et al. Risks of discontinuing maintenance treatment in pregnant women with bipolar disorder. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 19, 1997; San Diego, Calif. Abstract NR116:97
174. Faedda GL, Tondo L, Baldessarini RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993;50:448-455
175. Omtzigt J, Los F, Hagenaars A, et al. Prenatal diagnosis of spina bifida aperta after first-trimester valproate exposure. Prenat Diagn 1992;12: 892-897
176. MRC Vitamin Study Research Group. Prevention of neural-tube defects: results of the medical research council vitamin study. Lancet 1991;338: 131-137
177. Stewart DE, Klompenhouwer JL, Kendall RE, et al. Prophylactic lithium in puerperal psychosis: the experience of three centers. Br J Psychiatry 1991;158:393-397
178. Wheeler EO, White PD, Reed EW, et al. Neurocirculatory anthenia (anxiety neurosis, effort syndrome, neurasthenia): a twenty-year follow-up study of 173 patients. JAMA 1950;142:878-890
179. Cowley DS, Roy-Byme PP. Panic disorder during pregnancy. J Psychosom Obstet Gynaecol 1989;10:193-210
180. Cohen LS, Sichel DA, Faraone SV, et al. Course of panic disorder during pregnancy and the puerperium: a preliminary study. Biol Psychiatry 1996;39:950-954
181. Northcott CJ, Stein MB. Panic disorder in pregnancy. J Clin Psychiatry 1994;55:539-542
182. Villeponteaux VA, Lydiard RB, Laraia MT, et al. The effects of pregnancy on preexisting panic disorder. J Clin Psychiatry 1992;53:201-203
183. George DT, Ladenheim JA, Nutt DJ. Effect of pregnancy on panic attacks. Am J Psychiatry 1987;144:1078-1079
184. Klein DF, Skrobala AM, Garfinkel DS. Preliminary look at the effects of pregnancy on the course of panic disorder (technical note). Anxiety 1994; 1:227-232
185. Cohen L. Prospective study of panic disorder during pregnancy and the postpartum period. In: Syllabus and Proceedings Summary of the 1996 Annual Meeting of the American Psychiatric Association; New York, NY: May 4-9, 1996; No. 25:11
186. Robinson L, Walker JR, Anderson D. Cognitive-behavioural treatment of panic disorder during pregnancy and lactation. Can J Psychiatry 1992;37: 623-626
187. Buttolph ML, Holland A. Obsessive compulsive disorders in pregnancy and childbirth. In: Jenike M, Baer L, Minichiello WE, eds. Obsessive Compulsive Disorders, Theory and Management. Chicago, Ill: Yearbook Medical Publishers; 1990
188. Ingram IM. Obsessional illness in mental hospital patients. J Ment Sci 1961;107:382-402
189. Neziroglu F, Anemone R, Yaryura-Tobias JA. Onset of obsessive-compulsive disorder in pregnancy. Am J Psychiatry 1992;149:947-950
190. Lo WH. A follow-up study of obsessional neurotics in Hong Kong Chinese. Br J Psychiatry 1967;113:823-832